THE VALUE OF MERCK GHI FUND
Bringing venture mentality along with the benefits of a strategic investorDIGITAL HEALTH FOCUS
- Digital Health Expertise: A team with deep expertise in digital health and healthcare operating experience
- Focused Investment Model: Providing expansion capital for existing businesses in a therapeutic and brand-agnostic manner
- Ability to Move Quickly: Streamlined investment process and autonomy to make deals
- Focus on Creating Value: Expert guidance from an experienced, entrepreneurial senior leadership team
- Venture Approach: Incented to create value for our portfolio companies
- Merck Capabilities: Access to leading science, supply chain, commercial channel, marketing and regulatory experts
- Global Reach: Connections to Merck's global operations and talent in more than 140 countries
Bill Taranto - President, GHI Fund
Bill Taranto is the President of the GHI Fund and responsible for all areas of investing. Bill has more than 25 years of health care experience and for 12 of these years he has been focused on healthcare investing. In addition to his experience in venture investing, Bill has more than a decade of management operations experience. Today Mr. Taranto is a member of the Merck Innovative Ventures Board, a group that manages the identification and funding of portfolio businesses; and is also Chairman of the GHI Fund LLC Management Board. Prior to joining Merck, Mr. Taranto spent 18 years at Johnson & Johnson in various venture capital, marketing, sales and business development roles. Before J&J, Mr. Taranto spent eight years in investment banking. Mr. Taranto has a Bachelor of Business Administration from St. Bonaventure University.
Larry Senour - Managing Director
Larry Senour is a Managing Director with responsibility for identifying opportunities in all areas of digital health. Mr. Senour has over 25 years of healthcare experience in strategy, operations and transaction roles, including the last 17 years with Merck. Prior to joining GHI he served five years in Corporate Development, with responsibility for the identification, evaluation, structuring and negotiation of acquisitions, strategic alliances, joint ventures and corporate divestitures. Previously Larry served in Business Development and Licensing roles within Merck, and also had oversight responsibility for Merck Capital Ventures, a legacy venture fund which invested in emerging businesses with technologies in areas related to the discovery, development and commercialization of pharmaceuticals and related healthcare services. Before joining Merck, Larry spent four years in the Deloitte healthcare consulting practice and four years with Healthcare Services Group. Larry received his MBA from the University of Michigan and his BA from Pennsylvania State University.
Joel Krikston - Managing Director
Joel Krikston is a Managing Director focused on identifying new investment opportunities in Clinical Awareness & Decision Support and Quality & Performance Improvement. Mr. Krikston has over 20 years of experience in healthcare innovation. Prior to joining GHI, he was an Investment Principal at Johnson & Johnson Development Corporation, leading the group's efforts in healthcare technology and diagnostics. During Mr. Krikston's seven years with Johnson & Johnson, he served in a range of business development roles at both the corporate and operating company level focused on the identification, formation, development and launch of new businesses in emergent healthcare segments. He also spent eight years as an investment banker, covering an array of healthcare clients and included experience at BNP Paribas, JPMorgan and ABN Amro. Mr. Krikston has an MBA with honors from the Stern School of Business at NYU and completed his Bachelor's degree in Finance and International Business at Fairfield University.
David Rubin - Managing Director
David M. Rubin, Ph.D., is a Managing Director focused on precision medicine and has spent more than 20 years in the healthcare industry. Before joining the GHI team, Dr. Rubin managed Merck’s efforts in MRL Oncology, including the development of franchise strategies, and portfolio valuation. David joined Merck from Cognia Corporation, a venture-backed international healthcare R&D software company, where he was CEO. Previously, Dr. Rubin was at The Wilkerson Group/IBM Global Services. Dr. Rubin holds a Ph.D. from Temple University in Molecular Biology and a B.A. from SUNY Binghamton in Biology. He was a National Institutes of Health and American Cancer Society Post-Doctoral fellow at Harvard Medical School where he worked on the Ubiquitin Proteasome Pathway. He also received training in post-graduate business at Harvard University.
Dave Stevenson - Managing Director
Dave Stevenson is Managing Director responsible for identifying opportunities in all areas of digital health, with a particular focus on Provider & Patient Engagement. Mr. Stevenson also manages the GHI portfolio and operations. Mr. Stevenson brings more than 20 years of healthcare strategy and operations expertise to the GHI team. Prior to Merck GHI, Mr. Stevenson was AVP of U.S. Strategy at Sanofi-Aventis responsible for development of the company’s new commercial models. Before Sanofi-Aventis, Mr. Stevenson was with Ernst & Young/Capgemini as a growth strategy consultant across the healthcare industry. Mr. Stevenson started his career with Sandoz/Novartis where he built their first clinical trial management system. Mr. Stevenson holds a MBA from Vanderbilt University and a B.A. from Washington University.
Joe Volpe - Managing Director
Joe Volpe is a Managing Director responsible for identifying opportunities in health information technology platforms. Mr. Volpe has more than 25 years of experience in health care investing applying a technical engineering background coupled with an understanding of emerging technologies in the health care. Prior to joining Merck, Mr. Volpe spent more than a decade with J&J Corporate Innovations division and strategic development group dealing with consumer, device and pharmaceutical companies developing health care strategies and investments, including physician systems, managed markets platforms, e-prescribing organizations, consumer and professional sales, and marketing. Mr. Volpe began his career as a Systems Engineer with Electronic Data Systems (EDS) working with health care insurance systems, military systems and robotics. He holds a B.S. from the University of South Florida.
Francesca Wuttke - Managing Director
Francesca Domenech Wuttke, Ph.D. is a Managing Director focused on identifying new investment opportunities in Europe. Dr. Wuttke brings with her broad drug development and healthcare expertise in both the US and Europe, with over 20 years of clinical, commercial, strategic and transactional experience. She has worked with diverse organizations including start-ups, consulting, large and specialty pharma as well as academia. Most recently Dr. Wuttke led Almirall´s Corporate Development Strategy team to transact on both med device and pharma M&A opportunities with a new and targeted focus for the company. Before that Dr. Wuttke worked at Novartis where she was responsible for the assessment and development of novel commercial models around two Cell and Gene therapy opportunities that were successfully brought into the organization as well as managing the strategy and commercialization for the existing portfolio of cell therapy assets. Prior to that Dr. Wuttke sourced, diligenced and executed on structure finance transactions at Symphony Capital as well as licensed and spun-out university inventions at Mount Sinai School of Medicine. She began her career managing clinical trials at Beth Israel´s AIDS Clinical Trials Unit. Dr. Wuttke holds a Ph.D. in Pharmacology from Weill Cornell Graduate School of Medical Sciences and a BA from Cornell University College of Arts and Sciences.
President, GHI Fund